Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?

Executive Summary

GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.

You may also be interested in...



Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA

Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent

Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics

Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)

Watson Inventory Reserves Reflect Delayed Launch Of Wellbutrin SR Generics

Watson is taking an inventory reserve to account for the delayed launch of its "authorized" generic of GlaxoSmithKline's Wellbutrin SR (bupropion sustained-release)

Related Content

UsernamePublicRestriction

Register

PS041948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel